Lee's plans China depression drug sales
This article was originally published in Scrip
Hong Kong-based Lee's Pharmaceutical's China registration study of anti-depressant Trittico (trazodone) met its primary endpoint – enabling the firm to submit an import drug license application by the end of the year.
You may also be interested in...
Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.
Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.
In the most recent installment of In Vivo's VC Playbook column, former Amgen R&D lead Sean Harper talks exclusively about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.